[Table_ReportDate] 2025 年 11 月 24 日 [Table_ReportType] 医药生物行业周报（11 月第 3 周） [Table_S 行业ummary 观点：] [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 医药生物 G IVD 巨头共识下注肿瘤早筛 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（11 月 17 日-11 月 21 日）医药生物 板块收跌 6.88%，跑输 Wind 全 A（-5.13%）和沪深 300 （-3.77%）。从细分板块来看，所有子板块均收跌，原 料药（-8.6%）、线下药店（-8.58%）和其他生物制品 领跌（-7.99%）领跌。从个股来看，海南海药（23.8%）、 *ST 长药（19.7%）和*ST 苏吴（15.5 ...

把握回调后的机会，积极布局 2026 年 医药生物 证券研究报告/行业定期报告 2025 年 11 月 24 日 执业证书编号：S0740519040001 Email：zhujq@zts.com.cn | 上市公司数 | 498 | | --- | --- | | 行业总市值(亿元) | 70,594.11 | 消费多点开花》2025-11-17 2、《医保国谈落下帷幕；关注乳腺 癌创新疗法动向》2025-11-10 3、《改善趋势延续，积极把握底部 反转机会》2025-11-07 | 评级： | 增持（维持） | | | 重点公司基本状况 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | 分析师：祝嘉琦 | | | | （元） | 2023A | 2024A | 2025E | 2026E | 2027E | 2 ...

Investment Rating - The report indicates a neutral investment rating for the pharmaceutical industry, suggesting that the industry is expected to perform in line with the overall market [23]. Core Insights - The pharmaceutical sector experienced a decline of 6.9% this week, underperforming compared to the Shanghai Composite Index, which fell by 3.9% [3][5]. - The overall valuation of the pharmaceutical sector stands at 28.9 times earnings, ranking it 10th among 31 primary sectors [5][3]. - Key events include the acceptance of a new drug application for 百利天恒's drug iza-bren, which showed promising results in clinical trials for nasopharyngeal cancer [9]. - 泽璟制药's ZG006 received orphan drug designation from the FDA, indicating its potential in treating neuroendocrine cancer [10]. - 盟科药业 decided to terminate its stock issuance plan due to disagreements among major shareholders [11]. Market Performance - The pharmaceutical index's performance ranked 26th out of 31 sectors, with various sub-sectors showing significant declines, including raw materials (-8.6%) and chemical preparations (-6.8%) [3][5]. - The report highlights a focus on innovative drug sectors and medical devices, with specific companies recommended for investment [2]. Recent Key Events - 百利天恒's drug iza-bren demonstrated a complete response rate of 54.6% compared to 27.0% for standard chemotherapy, indicating its effectiveness [9]. - ZG006 showed an overall response rate of 38.5% in late-stage neuroendocrine cancer patients, with no severe adverse reactions reported [10]. - 盟科药业's stock issuance plan was halted due to internal conflicts, which may impact its operational stability [11].

泽璟制药公告，近日，公司在研产品注射用 ZG006 获得美国食品药品监督管理局（FDA）颁发孤儿药 资格认定（Orphan-drug Designation），用于治疗神经内分泌癌。ZG006 是公司通过其双/多特异性抗体 研发平台开发的一个三特异性抗体药物，已获得美国 FDA 和中国 NMPA 临床试验许可，并已分别被国 家药品监督管理局药品审评中心纳入突破性治疗品种，和被美国 FDA 授予孤儿药资格认定（Orphan- drug Designation）。 ...

Macroeconomic and Strategy Research - The U.S. job market remains resilient, with initial jobless claims unexpectedly dropping to the lowest level since June, indicating a strong employment situation [2] - The U.S. government has postponed the deadline for "reciprocal tariffs" to August 1, imposing tariffs ranging from 25% to 40% on 14 countries, leading to a stalemate in tariff negotiations with major economies [2][3] - Domestic CPI growth turned positive in June, driven by rising energy prices, while PPI continues to face downward pressure due to weak demand [2][3] Fixed Income Research - The overall interest rates have slightly increased, with the yield curve flattening, influenced by expectations of new real estate policies and regulatory pressures on local banks [4][5] - The central bank has net withdrawn nearly 800 billion yuan in the open market, leading to a slight rise in funding prices, while maintaining a generally loose monetary environment [5][6] - The primary market saw limited supply pressure, with a total issuance of 62 bonds amounting to 621.7 billion yuan, indicating a stable funding environment [5][6] Industry Research - The pharmaceutical and biotechnology sector is experiencing a surge in performance forecasts, with significant announcements such as Merck's $10 billion acquisition of Verona and the approval of new drugs [8][9] - The Shanghai Composite Index rose by 1.40%, with the pharmaceutical sector increasing by 0.88%, indicating positive market sentiment towards the industry [10] - The report suggests focusing on investment opportunities related to innovative drugs and the supply chain, particularly in sectors benefiting from policy optimization and improving overseas demand [10]

Investment Rating - The industry is rated as "Positive" for the next 12 months, indicating an expected increase in performance relative to the CSI 300 index [7][71][82]. Core Insights - The report highlights a concentrated period of semi-annual performance forecasts, suggesting a focus on pipeline realization, performance growth, and business collaborations in innovative drugs and related industry chains [7][70]. - Recent policy adjustments by the National Medical Insurance Administration are expected to catalyze innovation and development within the industry [14]. - Notable acquisitions and drug approvals, such as Merck's $10 billion acquisition of Verona and the approval of new drugs like the Bcl-2 inhibitor by Ascentage Pharma, are significant developments [2][27][14]. Industry Data - As of July 10, 2025, the SW pharmaceutical industry has a TTM price-to-earnings ratio of 28.55, with a valuation premium of 144% compared to the CSI 300 index [5][61]. - The report notes a general upward trend in various sub-sectors, with the medical services sector leading at a 1.56% increase [5][54]. - The report also provides insights into the pricing trends of raw materials, such as vitamins and traditional Chinese medicine, indicating fluctuations and year-on-year changes [15][17]. Company Announcements - Ascentage Pharma's Bcl-2 inhibitor has received conditional approval from the NMPA for treating chronic lymphocytic leukemia [27]. - WuXi AppTec anticipates a revenue increase of approximately 20.64% for the first half of 2025, with a significant net profit growth of about 44.43% [28]. - Gan & Lee Pharmaceuticals expects a net profit increase of 100.73% to 114.12% for the same period [29].

Market Overview - The A-share market is experiencing slight fluctuations, with the Shanghai Composite Index closing at 3387.40, down 0.04%, and the Shenzhen Component Index at 10151.43, down 0.12% [2][7] - The overall market capitalization of the Shanghai Composite Index is 6526.16 billion, with a price-to-earnings (PE) ratio of 12.03 and a price-to-book (PB) ratio of 1.25 [3] Industry Dynamics - The biomanufacturing sector is entering a critical phase, with a focus on overcoming the "pilot transformation" bottleneck to scale up the industry, aiming to cultivate over 20 pilot platforms by 2027 [26] - The storage chip market is witnessing price increases, with DDR4 prices rising by 17.50% week-on-week, and NAND products also showing price growth [29][30] - LG Energy Solution has secured an 8GWh order for cylindrical batteries from Chery Automobile, marking a significant contract in the electric vehicle battery supply chain [31] - The humanoid robot innovation center has established a subsidiary in Shenzhen, indicating growth in the robotics sector [33] - Meta and Oakley are launching smart glasses designed for sports, highlighting advancements in AI and wearable technology [35] Company Tracking - Wen's Foodstuffs (300498.SZ) reports continuous improvement in core production metrics for chicken and pig farming, with costs stabilizing [37] - Zhejiang Meida (002677.SZ) has announced an investment in smart driving technology, indicating a strategic shift towards emerging technologies [39] - Midea Group (000333.SZ) plans to repurchase shares worth between 50 to 100 billion, with a maximum repurchase price of 100 yuan per share [41] - Xinhua Medical (600587.SH) has received approval for a new medical device, enhancing its product portfolio in the healthcare sector [42] - Zai Jian Pharmaceutical (688266.SH) has received approval for clinical trials of its drugs for small cell lung cancer, marking a significant step in its oncology pipeline [44] - Ao Jing Medical (688613.SH) has obtained approval for its artificial bone repair material in Vietnam, expanding its market reach [47] - Bozhong Precision (688097.SH) is acquiring a 70% stake in Shanghai Wodian, enhancing its capabilities in industrial automation solutions [49]